AU2021338706A1 - Ribitol treatment - Google Patents

Ribitol treatment Download PDF

Info

Publication number
AU2021338706A1
AU2021338706A1 AU2021338706A AU2021338706A AU2021338706A1 AU 2021338706 A1 AU2021338706 A1 AU 2021338706A1 AU 2021338706 A AU2021338706 A AU 2021338706A AU 2021338706 A AU2021338706 A AU 2021338706A AU 2021338706 A1 AU2021338706 A1 AU 2021338706A1
Authority
AU
Australia
Prior art keywords
day
ribitol
dose
comprises administering
method comprises
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021338706A
Other languages
English (en)
Inventor
Qi Long Lu
Bo Wu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Carolinas Healthcare System
Original Assignee
Carolinas Healthcare System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Carolinas Healthcare System filed Critical Carolinas Healthcare System
Publication of AU2021338706A1 publication Critical patent/AU2021338706A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Molecular Biology (AREA)
AU2021338706A 2020-09-10 2021-09-09 Ribitol treatment Pending AU2021338706A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063076761P 2020-09-10 2020-09-10
US63/076,761 2020-09-10
PCT/US2021/049677 WO2022056137A1 (en) 2020-09-10 2021-09-09 Ribitol treatment

Publications (1)

Publication Number Publication Date
AU2021338706A1 true AU2021338706A1 (en) 2023-05-25

Family

ID=80629815

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021338706A Pending AU2021338706A1 (en) 2020-09-10 2021-09-09 Ribitol treatment

Country Status (10)

Country Link
US (1) US20230364118A1 (cg-RX-API-DMAC7.html)
EP (1) EP4210708A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023544249A (cg-RX-API-DMAC7.html)
KR (1) KR20230069941A (cg-RX-API-DMAC7.html)
CN (1) CN117355310A (cg-RX-API-DMAC7.html)
AU (1) AU2021338706A1 (cg-RX-API-DMAC7.html)
CA (1) CA3191582A1 (cg-RX-API-DMAC7.html)
IL (1) IL301088A (cg-RX-API-DMAC7.html)
MX (1) MX2023001881A (cg-RX-API-DMAC7.html)
WO (1) WO2022056137A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10434113B2 (en) 2016-12-16 2019-10-08 The Charlotte Mecklenburg Hospital Authority Compositions and methods for treating muscular dystrophy and other disorders
CN114269712A (zh) 2019-05-28 2022-04-01 夏洛特-梅克伦堡医院管理局D/B/A艾奇恩健康 制备核糖醇的组合物和方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10245235B2 (en) * 2016-12-16 2019-04-02 The Charlotte-Mecklenburg Hospital Authority Compositions and methods for treating muscular dystrophy and other disorders
WO2020041750A1 (en) * 2018-08-24 2020-02-27 The Charlotte Mecklenburg Hospital Authority D/B/A Atrium Health Methods and compositions for treating disorders associated with muscle weakness

Also Published As

Publication number Publication date
WO2022056137A1 (en) 2022-03-17
US20230364118A1 (en) 2023-11-16
EP4210708A4 (en) 2024-10-23
WO2022056137A9 (en) 2022-04-14
JP2023544249A (ja) 2023-10-23
KR20230069941A (ko) 2023-05-19
CA3191582A1 (en) 2022-03-17
CN117355310A (zh) 2024-01-05
MX2023001881A (es) 2023-04-03
IL301088A (en) 2023-05-01
EP4210708A1 (en) 2023-07-19

Similar Documents

Publication Publication Date Title
US12427161B2 (en) Methods for treating and pharmaceutical compositions
JP6612370B2 (ja) ポンペ病の処置のための投与計画
JP2026035578A (ja) ファブリー病の治療用投薬レジメン
US20130245081A1 (en) Compositions and Methods for Treating Amyotrophic Lateral Sclerosis
TW200808324A (en) Method for shortening hospital stay in patients with congestive heart failure and acute fluid overload
RS67913B1 (sr) Postupci lečenja fabrijeve bolesti
US20230364118A1 (en) Ribitol treatment
US20200061092A1 (en) Methods and compositions for treating disorders associated with muscle weakness
WO2012154779A1 (en) Combinations of oxybutynin and salivary stimulants for the treatment of overactive bladder
WO2025212841A1 (en) Compositions and methods for treating diseases and disorders associated with muscle weakness
JP2014513689A (ja) 過活動膀胱の治療のためのトロスピウムと唾液分泌刺激剤の組合せ
HK40112795A (en) Dosing regimens for the treatment of pompe disease
AU2024349468A1 (en) Emrusolmin for use in treating multiple system atrophy
HK40036814A (en) Dosing regimens for the treatment of fabry disease
WO2012154778A1 (en) Combinations of imidafenacin and salivary stimulants for the treatment of overactive bladder